Introduction {#Sec1}
============

Methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-resistant coagulase-negative staphylococci (MRCoNS) represent main causes of hospital- and community-acquired infections; because of their increasing numbers and elevated mortality, morbidity, and medical expenses, they have become a global concern in recent years \[[@CR1], [@CR2]\]. Staphylococci contain virulence factors and toxins that cause various diseases including blood, skin and soft tissues infections, nosocomial infections connected with the presence of medical devices, and toxic shock syndrome \[[@CR3]\]. The *mecA* gene, located in the SCCmec region, is responsible for the expression of methicillin resistance through PBP2a---an altered penicillin-binding protein that is characterized by its low affinity to penicillin and other beta-lactam drugs \[[@CR4]\]. For both MRSA and MRCoNS vancomycin is used as the first line drug for treatment. However, in recent years, decreased susceptibility and even resistance to vancomycin and other antibiotics, including aminoglycosides, tetracyclines, and lincosamides, have been reported in many parts of the world \[[@CR5]--[@CR7]\]. Therefore, for the treatment of severe infections caused by multi-drug resistant staphylococci, new antibiotics such as daptomycin, linezolid, tigecycline, and Quinupristin/Dalfopristin (Q/D) were introduced \[[@CR8]\]. Daptomycin, a cyclic lipopeptide antibiotic, is the second most important anti-MRSA drug, which received FDA approval in 2003 and approval by the European Medicines Agency (EMA) in 2005. It is mostly used for the treatment of acute bacterial skin and soft tissues infections \[[@CR9]\]. Daptomycin is still quite active against staphylococci and enterococci; however, resistance to this antibiotic has been reported over the past years due to mutation of various genes (*dltABCD* genes, *mprF* and *rpoB*), causing changes in membrane fluidity, cell wall thickness, and membrane charge \[[@CR10], [@CR11]\]. Tigecycline is an example of a new class of broad-spectrum antimicrobial agents known as glycylcyclines with activity against Gram-positive and Gram-negative organisms. This antibiotic was approved by FDA (2005--2009) for the treatment of skin infections, intra-abdominal infections and community-acquired bacterial pneumonia \[[@CR12], [@CR13]\]. Tigecycline provides an alternative treatment for complicated MRSA and vancomycin resistant enterococci (VRE) infections; due to mutations in *mep*R and *mep*A genes that result in overexpression of efflux pumps, resistant phenotypes have been reported in recent studies \[[@CR13]\]. Linezolid is another new antibiotic that was approved in 2000 for the treatment of MRSA and MRCoNS infections and infections caused by VRE. Linezolid binds to the 50S ribosomal subunit of the 23S rRNA molecule and inhibits protein synthesis. *Cfr* gene encodes a methyltransferase that modifies the 23S rRNA site of the 50S ribosomal subunit and prevents linezolid from binding to it \[[@CR14]\]. Q/D is composed of two streptogramins (70% dalfopristin (streptogramin A) and 30% quinupristin (streptogramin B)), which was approved in 1999 as a treatment option for VRE and MRSA infections. This drug consists of quinupristin that inhibits late-stage protein synthesis, while dalfopristin inhibits early-stage protein synthesis. It should be noted that, Synercid® (formerly RP59000; Rhone-Poulenc) is the first semisynthetic injectable streptogramin and it is used as a trade name for Q/D \[[@CR15], [@CR16]\]. The World Health Organization (WHO) has considered MRSA as important antibiotic-resistant bacteria and put them on their priority list. All organisms on that list require new treatment modalities and substantiate an urgent overall need for new antimicrobial drugs \[[@CR17]\]. According to the authors' knowledge, no comprehensive data are available on the resistance levels to daptomycin, Q/D, linezolid, and tigecycline among MRSA and MRCoNS strains. This study aims to investigate the prevalence of resistance to the mentioned antibiotics among staphylococcal strains isolated from clinical samples around the world.

Methods {#Sec2}
=======

We conducted a literature search through databases, including web of science, EMBASE, and Medline (via PubMed), using the versions of September 2018. The historic publication year was unrestricted and the search was limited to original articles. The following search keywords were obtained from the National Library of Medicine's medical subject heading (MeSH) terms or titles or abstracts with the help of Boolean operators (and, or): "staph", "staphylococcus", "staphylococci", "staphylococcal", "staphylococcaceae" and "Linezolid", "Daptomycin", "Tigecycline", "Quinupristin/Dalfopristin", and "Synercid". Two independent reviewers screened the titles and abstracts of original articles and posters; if an article appeared relevant (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}), the full text was reviewed. We used the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for daptomycin, linezolid, Q/D resistance and tigecycline resistance in Staphylococci, respectively (there is no standard for tigecycline in staphylococci in the CLSI). The resistance cut-off rates are defined in the following ranges ≤1 mg/L, ≥8 mg/L, ≥4 mg/L, and \> 5 mg/L, respectively. We considered all articles that evaluated antibiotic resistance by different methods such as broth microdilution (BMD), agar dilution, disk diffusion (DD), E-test and Vitek or Vitek 2 or any other automated instruments. It should be noted that, the final version of the CLSI (2018) states that staphylococci with resistant results to linezolid by DD should be confirmed by using an MIC method, therefore, studies that only used the DD method for susceptibility to the linezolid were excluded. Moreover, case reports, basic research on the resistance mechanism of the mentioned antibiotics, and review articles were excluded from this study. Fig. 1Flow chart detailing review process and study selection for linezolid and daptomycin

Meta-analysis {#Sec3}
-------------

### Quality assessment {#Sec4}

All reviewed studies were subjected to a quality assessment (designed by the Joanna Briggs Institute) and only high-quality investigations were evaluated in our final analysis \[[@CR18]--[@CR116]\].

### Data analysis {#Sec5}

The analysis was performed by STATA (version 14.0) software. The data were pooled using a fixed effects model (FEM) \[[@CR117]\] and a random effects model (REM) \[[@CR118]\]. Statistical heterogeneity was assessed by statistical methods \[[@CR119]\] and was evaluated using the Q-test and the I2 statistical methods \[[@CR118]\]. *P*-value \< 0.1 was regarded as statistically significant \[[@CR120]\].

Results {#Sec6}
=======

This study identified 1813, 2222, 512, and 636 articles for daptomycin, linezolid, Q/D (Synercid), and tigecycline, respectively, in the first step. Then, upon secondary screening, a large number of articles were excluded on the basis of title and abstract evaluation because of the lack of relevance to the study principles, and the reasons for the deletion of these articles are presented in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}. Therefore, 477, 768, 124, and 214 articles for the mentioned antibiotics were reviewed with full text, and a number of papers were excluded from the study for the reasons listed in Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}. Finally, 37, 51, 17, and 22 eligible studies for daptomycin, linezolid, Q/D, and tigecycline were chosen for final analysis, respectively. Resistance percentage in *S. aureus*, MRSA and CONS to the mentioned antibiotics is shown in Table [1](#Tab1){ref-type="table"}. The characteristics of the included articles are summarized in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}. All pertinent studies were included from around the world (25 different countries) (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). The USA was the most frequently represented country for all antibiotics followed by Canada and European countries (Italy and Spain). From the African continent, only one study from Nigeria, where tigecycline resistance in one isolate was reported (Fig. [3](#Fig3){ref-type="fig"}). Linezolid-resistant staphylococci from 15 countries were included in the present study, which was more widely distributed among antibiotics (Fig. [4](#Fig4){ref-type="fig"}). Strains were isolated from various clinical samples including blood, wound, skin, urine, respiratory tract, sputum, catheter, bone, etc. A majority of studies used BMD, E-test, agar dilution, disk diffusion, and Vitek or vitek 2. Our results showed that linezolid had the best inhibitory effect on *S. aureus.* Although resistance to the linezolid has been reported from different countries, due to the high volume of the samples and the low number of resistance, in terms of statistical analyzes, the resistance to this antibiotic is zero*.* Moreover, linezolid and tigecycline effectively (99.9%) inhibit MRSA (Table [1](#Tab1){ref-type="table"}). Studies have shown that CoNS with 0.3% show the lowest resistance to linezolid and daptomycin, while analyzes introduced tigecycline with 1.6% resistance as the least effective antibiotic for these bacteria. Finally, MRSA and CoNS had a greater resistance to Q/D with 0.7 and 0.6%, respectively. Fig. 2Flow chart detailing review process and study selection for Q/D and tigecyclineTable 1Resistance percentages in *S. aureus*, MRSA and CoNS to different antibiotics***S. aureus***LinezolidDaptomycinTigecyclineQ/DResistance rate (%)0.0%\[CI% (0.0--0.0)\]0.1 \[CI% (0.1--0.1)\]0.1 \[CI% (0--0.1)\]0.1 \[CI% (0.1--0.2)\]p-value0.040.020.090.88**MRSA**Resistance rate (%)0.1 \[CI% (0--0.1)\]0.1 \[CI% (0.1--0.1)\]0.1 \[CI% (0--0.1)\]0.7 \[CI% (0.3--1)\]p-value0.330.000.000.00**CoNS**Resistance rate (%)0.3 \[CI% (0.2--0.4)\]0.3 \[CI% (0.2--0.4)\]1.6 \[CI% (1.2--1.9)\]0.6 \[CI% (0.3--0.9)\]p-value0.040.370.000.00MRSA; Methicillin-resistant *Staphylococcus aureus*, CoNS; Coagulase-negative staphylococci, Q/D; Quinupristin / DalfopristinTable 2Characteristics of the articles that were included in the meta-analysis and reported resistance to tigecyclineFirst nameTime of studyPublished timeCountryTotal staphylococcus*S. aureus*MRSACoNS*S. aureus*\
Tigecycline-ResistantMRSA Tigecycline- ResistantCoNS Tigecycline -ResistantSusceptibility testing methodIsolation sourceMorrissey \[[@CR76]\]20112012Germany81434338116BMDBacteraemia and Skin infectionAyepola \[[@CR20]\]2015Nigeria209209611Automated VITEK-2 systemClinical specimensGarza-González E \[[@CR48]\]20092013Honduras61612111BMDUrine, Blood, Respiratory tract, Skin, Wound, Body fluidGarza-González E \[[@CR48]\]20092013El Salvador34341922BMDUrine, Blood, Respiratory tract, Skin, Wound, Body fluidXi \[[@CR112]\]2014--20162018China151311211DDClinical specimensWang \[[@CR111]\]2006--20102015Taiwan67067067033Automated VITEK-2 systemBlood infectionAdam \[[@CR18]\]2007--20112013Canada41774177126663BMDBlood, Respiratory tract, Urine, WoundCassettari \[[@CR28]\]2010--20112011Italy2802011027911BMDSkin and soft tissue infections, Hospital-acquired pneumoniaBongiorno \[[@CR25]\]20122018Italy50505022BMDLower respiratory tract infections, Skin and soft-tissue, BloodZhanel \[[@CR114]\]2007--20112013Canada662354432500118084BMDWound, Urinary tract, BloodFlamm \[[@CR40]\]20102012USA40493105157894421BMDBlood, Pneumonia, SkinFlamm \[[@CR41]\]20132015USA34333035145439811BMDBlood, Skin, Soft tissueYousefi \[[@CR113]\]2014--20152017Iran54545422BMDUTIHodile \[[@CR51]\]2010--20142017France44044032552BMDBronchopulmonary infectionsChen \[[@CR30]\]2006--20102014Taiwan17251725172511BMDBlood, PusZhanel \[[@CR115]\]2007--20092011Canada3910358988932151BMDWound, Urinary tract, Blood, Respiratory tractVega \[[@CR110]\]2004--20152017Latin America45634563220242BMDClinical specimensSader \[[@CR93]\]2006--20122014USA28,27828,27814,75622BMDBlood, Wound, Skin, PneumoniaPutnam \[[@CR86]\]2004--20082010USA18,91718,91710,24233BMDSkin, Intra-abdominal, BacteraemiaKarlowsky \[[@CR65]\]2011--20152017Canada376034087281814BMDUrine, Blood, Respiratory tract, Skin, Wound, Body fluidMorrissey \[[@CR76]\]20112012Italy824141411BMDBacteraemia, Skin infectionBrzychczy-wolch \[[@CR26]\]20092013Poland1001005DDBlood, PneumoniaJan \[[@CR56]\]2006--20092012France2162661904Agar dilutionImplantable cardioverter defibrillator infectionSader \[[@CR101]\]2000--20042005USA12,3358765305035705080BMDBloodAbbreviations: DD; disk diffusion, BMD; broth microdilutionTable 3Characteristics of the articles that were included in the meta-analysis and reported resistance to Q/DFirst nameTime of studyPublished timeCountryTotal staphylococcus*S. aureus*MRSACoNS*S. aureus*\
Q/D-ResistantMRSA Q/D- ResistantCoNS Q/D-ResistantSusceptibility testing methodIsolation sourcePetrelli \[[@CR79]\]2003--20042007Italy3737161DDBlood infectionMcDonald \[[@CR72]\]1998--20002004Taiwan55440024015411BMDBlood, Urine, Wound, Respiratory tractLuh \[[@CR69]\]1996--19992000Taiwan554149804051132Agar dilutionBlood, Respiratory tract, Cerebrospinal fluid, Bile, Wound, Rectal swabPicazo \[[@CR85]\]20102011Spain702503187199113BMDMedical cantersSader \[[@CR103]\]2002--20042006Germany123271551711BMDSkin infection, BloodSader \[[@CR103]\]2002--20042006Italy6853862991BMDSkin infection, BloodSader \[[@CR103]\]2002--20042006UK593531621BMDSkin infection, BloodDraghi \[[@CR36]\]20042005USA3368287215564962BMDSkin, Blood, Respiratory tractBallow \[[@CR21]\]2002North America11,671703827214633101020BMDMedical cantersDecousser \[[@CR34]\]20002003France3642428712211E-testBloodHsueh \[[@CR52]\]1991--20032005Taiwan10010010011Agar dilutionClinical specimensLimoncu \[[@CR68]\]2003Turkey14914952305BMDClinical specimensJones \[[@CR59]\]1996--19972001USA17781290623488761DDWound, Abdominal cavity, Respiratory tract, Urinary tract, BloodAnastasiou \[[@CR19]\]2001--20032008North America36036036066BMDHospitalPicazo \[[@CR82]\]20082009Spain70352020118355BMDBloodJones \[[@CR63]\]20072008USA433833181930102022BMDMedical cantersPfaller \[[@CR80]\]2002--20052010USA13,05310,917494721361BMDMedical cantersJohn \[[@CR58]\]2002Canada65865815Agar dilutionPatient in hospitalsSader \[[@CR103]\]2002--20042006France14791100379167BMDSkin infection, BloodSader \[[@CR103]\]2002--20042006Greece185128572BMDSkin infection, BloodSader \[[@CR103]\]2002--20042006Turkey4622911712BMDSkin infection, BloodKhan \[[@CR66]\]2012--20132014Saudi Arabia1901904Microscan Walk Away system (40si, siemens)BloodAbbreviations: DD; disk diffusion, BMD; broth microdilutionTable 4Characteristics of the articles that were included in the meta-analysis and reported resistance to daptomycinFirst nameTime of studyPublished timeCountryTotal staphylococcus*S. aureus*MRSACoNS*S. aureus* Daptomycin-ResistantMRSA Daptomycin - ResistantCoNS Daptomycin-ResistantSusceptibility testing methodIsolation sourceMorrissey \[[@CR76]\]20112012Italy82414141331BMDBacteraemiaMendes \[[@CR75]\]2007--20092010USA40774077407766BMDBacteraemia, PneumoniaBiedenbach \[[@CR22]\]2003--20042007Australia1559125748030211BMDSkin, Blood, Respiratory tract infectionPicazo \[[@CR84]\]2001--20102011Spain11301130113011BMDMedical cantersPicazo \[[@CR83]\]2001--20062010Spain118675575543111BMDBloodVamsimohan \[[@CR109]\]20112014India50503022E-testWound, Pus swabPfaller \[[@CR80]\]2002--20052010USA13,05310,91749472136524BMDMedical centersJevitt \[[@CR57]\]1996--20012003USA119884731332BMDMedical centersRouse \[[@CR91]\]1985--20052007USA184686811622BMDEndocarditis, Joint infectionRolston \[[@CR88]\]20112013USA1651067259113E-testSurgical wounds, Pleural, Ascitic fluidCuny \[[@CR32]\]2011--20132015Germany19521952195277BMDBloodSader \[[@CR100]\]2007--20082009USA9230807745141153886BMDBlood, Skin, PneumoniaKao \[[@CR64]\]2006--20082011Taiwan47047047022BMDBloodJain \[[@CR54]\]2011--20122013India736831533E-testSoft tissue, Blood, Intra-abdominal infectionJones \[[@CR63]\]20072008USA4338331819301020434BMDMedical centersJones \[[@CR60]\]20062007USA37212913164880833BMDPneumonia, Wound, Urinary tractSader \[[@CR102]\]2005--20102011USA22,85822,85812,1811312BMDBloodFlamm \[[@CR40]\]20102012USA40493105157894455BMDBlood, Pneumonia, SkinFarrell \[[@CR38]\]20082009USA401231561752856336BMDPneumonia, Wound, Urinary tractFlamm \[[@CR41]\]20132015USA34333035145439811BMDBlood, Skin, Soft tissueKarlowsky \[[@CR65]\]2011--20152017Canada3760340872811BMDUrine, Blood, Respiratory tract, Skin, Wound, Body fluidSader \[[@CR94]\]2009--20132015USA44264426201377BMDBloodChen \[[@CR30]\]2006--20102014Taiwan17251725172522BMDBlood, PusMendes \[[@CR74]\]2007--20092012USA9282804242781240883BMDBacteraemia, Respiratory tractRichter \[[@CR87]\]20092011USA421042102247109BMDWound Blood, Lower respiratory tract, and Joint fluid.Biswas \[[@CR23]\]20102012India11580803555E-testAbscesses, Wound, SkinMorrissey \[[@CR76]\]20112012Germany814343383BMDBacteraemiaHellmark \[[@CR50]\]1993--20032009Sweden33331E-testInfected Hip prosthesesKhan \[[@CR66]\]2012--20132014Saudia Arabia1901903Microscan Walk Away system(40si,siemens)BloodPicazo \[[@CR84]\]20102011Spain70250318719911BMDMedical centersIsnard \[[@CR53]\]2011--20142018France200100191001BMDProsthetic joint infectionsSader \[[@CR99]\]20032005Latin America7875361432511BMDMedical centersMathai \[[@CR71]\]20062007India111174133537011BMDMedical centersSader \[[@CR97]\]2002--20062008USA802764973143153014BMDBloodDraghi \[[@CR35]\]2004--20052008USA26712299108237242BMDMedical centersStuart \[[@CR107]\]2011Canada6336337Agar dilution methodClinical isolatesGales \[[@CR45]\]2005--20082009Brazil303022186878122BMDBlood, Skin, PneumoniaGallon \[[@CR46]\]2006--20072009France498531E-testAbscess, whitlows, diabetic foot infections, impetigo, Furunculosis, wounds infections, cellulite, etc.Zhanel \[[@CR116]\]2005--20062008Canada10461622BMDBlood, urine, wound/tissue, respiratory specimensSader \[[@CR104]\]20052007Italy4221821BMDBlood, Skin, PneumoniaAbbreviations: BMD; broth microdilutionTable 5Characteristics of the articles that were included in the meta-analysis and reported resistance to linezolidFirst nameTime of studyPublished timeCountryTotal staphylococcus*S. aureus*MRSACoNS*S. aureus* Linezolid-ResistantMRSA Linezolid - ResistantCoNS Linezolid-ResistantSusceptibility testing methodIsolation sourceMendes \[[@CR75]\]2007--20092010USA40774077407755BMDBacteraemia, PneumoniaCassettari \[[@CR28]\]2010--20112011Spain29923711362111BMDSkin and soft tissue infections, hospital-acquired pneumoniaJain \[[@CR55]\]2011--20142015India2008200838433E-testDuncan \[[@CR37]\]2013--20142016USA1353135367611BMDPneumoniaFarrell \[[@CR39]\]2008--2092011USA4073325716738165512BMDBacteraemia, Pneumonias, Wound infection, PneumoniaBłażewicz \[[@CR24]\]2014--20152016Poland157157113BMDSkin, Nasal swabPicazo \[[@CR85]\]20102011Spain7025031871992216BMDMedical centersSader \[[@CR92]\]2005--20092010brazil263726378462BMDMedical centersJevitt \[[@CR57]\]1996--20012003USA1198847311BMDMedical centersCuny \[[@CR32]\]2011--20132015Germany19521952195211BMDBloodSader \[[@CR103]\]2002--20042006Greece185128571BMDSkin infection, BloodCampanile \[[@CR27]\]20122015Italy1684168464053Automated VITEK-2 system, Broth microdilutionLower respiratory tract, Skin and Soft tissuePicazo \[[@CR82]\]20082009Spain703520201183663BMDBloodSader \[[@CR100]\]2007--20082009USA92308077451411534420BMDBlood, Skin, PneumoniaFuchs \[[@CR44]\]2000--20022002USA10853285511BMDMedical centersSader \[[@CR97]\]2002--20062008USA649764973143153066BMDBloodFarrell \[[@CR38]\]20082009USA4012315617528563318Broth microdilution, E-testPneumonia, Wound, Urinary tractJones \[[@CR61]\]20072009Ireland141130111BMDBloodJones \[[@CR63]\]20072008USA43383318193019202218BMDMedical centersJones \[[@CR60]\]20062007USA3721291316488081113BMDPneumonia, Wound, Urinary tractRoss \[[@CR90]\]20022005USA455736871401870111BMDMedical centersMendes \[[@CR73]\]2002--20042008USA19891989198911BMDMedical centersFlamm \[[@CR40]\]20102012USA4049310515789442214BMDBlood, Pneumonia, SkinFlamm \[[@CR40]\]20132015USA343330351454398223BMDBlood, skin, soft tissuePutnam \[[@CR86]\]2004--20082010USA18,91718,91710,24233BMDBacteraemia, PneumoniaPfaller \[[@CR81]\]2011--20152017USA674130311391924117BMDMedical centersFlamm \[[@CR42]\]20142016USA39033106797225BMDBlood, Pneumonia, SkinSahm \[[@CR105]\]2011--20122015USA4186374344352BMDMedical centersTekin \[[@CR108]\]2007--20112014Turkey870907711114E-testBloodRosenthal \[[@CR89]\]20122014Haiti161641E-testDifferent ward of hospitalDecousser \[[@CR33]\]2004--20162018France343734379533BMDAll body sitesSader \[[@CR96]\]2008--20142016USA67067033921BMDSkin infectionHodille \[[@CR51]\]2010--20142016France44044032522BMDBronchopulmonary infectionsSader \[[@CR94]\]2009--20132015USA44264426201311BMDBloodSader \[[@CR95]\]2008--20112013USA22,62019,3509872327014951BMDBlood, Respiratory tract, SkinMendes \[[@CR74]\]2007--20092012USA92828042427812404419BMDBacteraemia, Respiratory tractRichter \[[@CR87]\]20092011USA42104210224711BMDWound, Blood, Lower respiratory tract, Joint fluidGales \[[@CR45]\]2005--20082009Brazil30302218687812112BMDBlood, Skin, PneumoniaSader \[[@CR98]\]2002--20062009USA14,00914,0092BMDCatheter related bloodstream infections (BSI)Castanheira \[[@CR29]\]20062008North America487342882251585114BMDBloodstream infections, Skin and soft tissue infections, PneumoniaMorrissey \[[@CR76]\]20112012Italy824141412BMDBacteraemiaMorrissey \[[@CR76]\]20112012Spain794545341BacteraemiaCui \[[@CR31]\]2009--20102013China7137134Agar dilutionBloodSong \[[@CR106]\]2013--20142017China110411043Agar dilutionBloodPedroso \[[@CR78]\]2008--20092018Brazil58581Automated VITEK-2 systemBloodLi \[[@CR67]\]20142016China179814996322992BMDPneumonia, Skin and soft tissue infection, Blood infectionIsnard \[[@CR53]\]2011--20142018France200100191002BMDProsthetic joint infectionsGandra \[[@CR47]\]2008--20142016India5426108960843371721BMDBloodDraghi \[[@CR36]\]20042005USA3368287215564961BMDSkin, Blood, Respiratory tractJones \[[@CR61]\]20072009Italy15198532BMDBloodMutnick \[[@CR77]\]2001--20022003USA5848467711711BMDBlood, Skin, Respiratory and Urinary tractJones \[[@CR62]\]20082009Italy12859692BMDMedical centersJones \[[@CR62]\]20082009France140100401BMDMedical centersMartinez \[[@CR70]\]20062013Mexico1421425BMDBloodZhanel \[[@CR116]\]2005--20062008Canada10461622Blood, urine, Wound/tissue, Respiratory specimensAbbreviations: BMD; broth microdilutionFig. 3The global prevalence of **a**) Tigecycline, **b**) Quinupristin/Dalfopristin-resistant *S. aureus*, MRSA and CoNSFig. 4The global prevalence of a) Daptomycin and b) linezolid-resistant *S. aureus*, MRSA and CoNS

Discussion {#Sec7}
==========

MRSA is a frequent cause of skin and soft tissue infection, pneumonia, endocarditis, bone and joint infection in individuals with some risk factors such as indwelling devices, surgical interventions, long-term antibiotic use, intensive care admission, and dialysis \[[@CR121], [@CR122]\]. In recent years, this bacterium has had very high health costs for patients due to increased length of hospital stay and longer duration of antibiotic treatment \[[@CR123]\]. Moreover, CoNS are opportunistic pathogens that lead to 30% of hospital-induced infections and 10% of uncomplicated urinary tract infections in young women and native valve endocarditis, especially in immunocompromised patients \[[@CR124], [@CR125]\]. Currently, the treatment of MRSA and CoNS is difficult due to the high antibiotic resistance to beta-lactams and other antibiotic classes, and newer agents such as linezolid, daptomycin, Q/D, and tigecycline can be used as alternative if available and deemed cost-effective. Accordingly, this study collected data from resistance to these antibiotics all over the world to determine the extent of their clinical application. The analysis of the results showed that linezolid had the highest inhibitory effect on *S. aureus*; due to the high volume of the samples in the studies and a small number of bacteria that have been reported as resistant (mostly in the United States), in terms of statistical analyses, the percentage of resistance to this antibiotic is zero (Table [1](#Tab1){ref-type="table"}). It should be noted that the studies (20 studies) that used the DD method as an antibiotic susceptibility test for linezolid were removed from this study and not entered into statistical analyses. Furthermore, the most linezolid-resistance *S. aureus* isolates isolated from pneumonia and blood infections were the highest in number. In addition to the good effect of linezolid on *S. aureus*, this drug also had the efficient activity against MRSA, while the resistance of CoNS was higher to this antibiotic. One of the reasons for the increased resistance in CoNS is the ability of these bacteria to develop resistance quite easily following linezolid exposure, even though this has not been proven in vitro, to the best of our knowledge. Furthermore, more Linezolid-resistant CoNS (LRCoNS) were associated with outbreaks; 50% of those studies that analysed LRCoNS involved clonal LRCoNS across one or more patients and facilities. The studies that used MLST for typing of resistant-linezolid CoNS, ST5, ST22 and for *S. aureus* ST228, ST8 and ST5 were reported to be more sequence types related to linezolid resistance \[[@CR25], [@CR67]\].

Tigecycline had the best effect (equal to linezolid) on MRSA, and very low resistance in *S. aureus* was observed; however, CoNS with 1.6% showed the highest percentage of resistance to this antibiotic (Table [1](#Tab1){ref-type="table"}). Since very few studies have reported the resistance of CoNS to tigecycline (Fig. [3](#Fig3){ref-type="fig"}), the high percentage of resistance noted by tigecycline cannot be deemed. The geographic diversity of the countries that reported the tigecycline resistance was higher than those with linezolid, thus showing more use of this antibiotic in different parts of the world. Recent MRSA infection treatment guidelines have not incorporated tigecycline. The reason is the FDA's September 2010 safety statement, which describes increased overall mortality among severely infected patients who are treated with tigecycline; besides, cause of the excess deaths in these trials usually remains uncertain. However, it is likely that most cases of death among such patients were associated with the infection progression. Moreover, this antibiotic is not authorized for pneumonia or diabetic foot infections. Although tigecycline is recommended for treating skin and soft tissue infections, previous studies have shown no significant difference between this antibiotic and other new drugs, and tigecycline is referred to as the second or third line of treatment for infections caused by MRSA \[[@CR126], [@CR127]\]. Therefore, although the present study showed that *S. aureus* resistance to tigecycline is low, the use of this drug still has limitations in treating staphylococcal infections. Daptomycin is another new drug used to treat infections caused by Gram-positive bacteria including MRSA and VRE. It kills microorganisms by rapid membrane depolymerisation, loss of membrane potential and disruption of DNA, as well as RNA and protein-synthesis \[[@CR128]\]. The daptomycin resistance among staphylococcal strains has been reported from around the world, although there has been no resistance report from the African continent. The United States had the highest rate of resistance (42.5% of studies); India, Taiwan, and Saudi Arabia reported resistance to this antibiotic from the Asian continent, and most of the bacteria were isolated from wounds and blood infections. In the United States and Europe, daptomycin is used for treating skin and soft tissue infections, bacteraemia, and endocarditis caused by *S. aureus* \[[@CR129]\]. Previous studies have reported that it is not very practical to use daptomycin for the treatment of pneumonia, because it is deactivated by pulmonary surfactants. Therefore, vancomycin and linezolid are recommended to treat pneumonia caused by MRSA \[[@CR130]\]. Our results have shown that daptomycin has the best performance with linezolid regarding CoNS, indicating that this antibiotic can be used for a therapeutic approach to infections caused by these bacteria. Furthermore, the present study showed that resistance to daptomycin has been very low (0.1--0.3%); considering that this antibiotic shortens the duration of the treatment of soft-tissue infections due to MRSA compared to vancomycin \[[@CR131]\], it can be used to a greater degree for treating the mentioned infections. However, spontaneous resistance to daptomycin seems to occur rarely \[[@CR132]\], and vancomycin can also decrease the function of this drug \[[@CR130], [@CR133]\]. Therefore, it is possible to isolate daptomycin-resistant strains from the areas where this antibiotic is not even used, and physicians usually use alternative agents (linezolid and vancomycin) instead of daptomycin, which can be considered as a factor. Daptomycin can be one of the choices for treating staphylococci-induced infections if there is a strong possibility based on local microbiological data or recent treatment history of vancomycin in an infected patient with MIC of \> 1 μg/mL.

Q/D comprises quinupristin and dalfopristin in a 30:70 ratio, which prevents protein synthesis in bacteria \[[@CR134]\]. Studies have shown that Q/D with 0.7% has the highest resistance rate amongst MRSA strains (Table [1](#Tab1){ref-type="table"}). Resistance reports were gathered from the continents of America, Asia, and Europe, although more studies have been carried out in European countries. This antibiotic is used for the treatment of VRE bloodstream infection and complicated skin and soft tissues infections caused by MRSA and *Streptococcus pyogenes*. However, the results of this study showed that Q/D had a weaker inhibitory effect than linezolid and daptomycin on *S. aureus*, MRSA, and CoNS (Table [1](#Tab1){ref-type="table"}); on the other hand, it has significant side effects (myalgia, arthralgia, increased alkaline phosphatase, and nausea), high drug interactions, and treatment costs \[[@CR135]\], which led to the limited use of this antibiotic. Therefore, it is better to use other new alternative antibiotics instead of Q/D for treating of staphylococcal infections. The present study showed that although linezolid, Q/D, daptomycin, and tigecycline are prescribed by clinicians for about 15 to 20 years, there is still very low resistance to these antibiotics around the world. On the other hand, with the increasing resistance of staphylococci to vancomycin and the high side effects of other drugs such as cotrimoxazole, it seems that these antibiotics have to be used more often in the future. The results of a recent study on the global prevalence of vancomycin-nonsusceptible MRSA showed that the prevalence of vancomycin-intermediate *S. aureus* (VISA) was 3.01% in 68,792 MRSA strains. Furthermore, the pooled prevalence of heterogeneous vancomycin-intermediate *S. aureus* (hVISA) was 6.05% and is highly dangerous, because these bacteria lead to higher rates of vancomycin treatment failure. It should be noted that this study reported that the rate of vancomycin-nonsusceptible MRSA has been increasing in recent years, and this is a danger to the international community \[[@CR136]\]. It should be noted that, still, some diseases caused by Staphylococcus genus, such as pneumonia, are treated easier with older drugs, and more studies are needed to evaluate the effect of the newer agents. The higher rates of resistance to the mentioned antibiotics in the United States and European countries compared to other parts of the world do not imply higher resistance to these antibiotics in this areas and are related to microbial susceptibility testing programs that are regularly carried out in these countries, while there are no such reports in the African and Asian countries (may because of non-availability and elevated prices in these regions). Therefore, by performing such programs in other countries, the exact resistance rates of the staphylococcal strains to the newer Gram-positive cocci antibiotics can be determined.

Conclusion {#Sec8}
==========

The present study shows that resistance to new agents is low in staphylococci and these antibiotics can still be used for treatment of staphylococcal infections in the world. It should be noted that the development of resistance to these antibiotics should be prevented by appropriate antibiotic resistance testing programs.

MRCoNS

:   Methicillin-resistant coagulase-negative staphylococci

PBP2

:   Penicillin-Binding Protein 2

FDA

:   Food and Drug Administration

EMA

:   European Medicines Agency

VRE

:   Vancomycin resistant enterococci

MeSH

:   Medical subject heading

CLSI

:   Clinical and Laboratory Standards Institute

EUCAST

:   European Committee on Antimicrobial Susceptibility Testing

BMD

:   Broth microdilution

REM

:   Random effects model

FEM

:   Fixed effects model
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